UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/575,099	02/06/2007	Shuji Terashima	P29763	9412	
	7590 09/17/201 & BERNSTEIN, P.L. <b>(</b>	-	EXAMINER		
1950 ROLAND	CLARKE PLACE		POPA, ILEANA		
RESTON, VA 20191			ART UNIT	PAPER NUMBER	
			1633		
			NOTIFICATION DATE	DELIVERY MODE	
			09/17/2010	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/575,099 TERASHIMA ET AL.		
Examiner	A 4   1     - 4	
Examiner	Art Unit	
ILEANA POPA	1633	

	ILEANA POPA	1633	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>27 August 2010</u> FAILS TO PLACE THIS AF	PLICATION IN CONDITION FOR	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A eplies: (1) an amendment, affidavit al (with appeal fee) in compliance	Appeal. To avoid abar ., or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
<ul> <li>a) The period for reply expires 4 months from the mailing date</li> <li>b) The period for reply expires on: (1) the mailing date of this Acono event, however, will the statutory period for reply expire late Examiner Note: If box 1 is checked, check either box (a) or (IMONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)</li> </ul>	dvisory Action, or (2) the date set forth it ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 ension and the corresponding amount of nortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS</li> </ol>	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
		20 ( ) ( )	
<ol> <li>The proposed amendment(s) filed after a final rejection, be (a)</li></ol>	sideration and/or search (see NOT v);	E below);	
(c) ☐ They are not deemed to place the application in bett appeal; and/or			ne issues for
(d) ☐ They present additional claims without canceling a c NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1 <sup>2</sup>		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (	PTOL-324)
5. Applicant's reply has overcome the following rejection(s):		inplication among the (	102 021).
<ol> <li>Newly proposed or amended claim(s) would be allenon-allowable claim(s).</li> </ol>	<del></del>	imely filed amendmer	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) [ how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation	of the status of the claims after er	ntry is below or attach	ed.
REQUEST FOR RECONSIDERATION/OTHER  11. The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:
<u>.</u>		sorialistrior anoman	
<ul> <li>12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (</li> <li>13. ☑ Other: <u>See Continuation Sheet</u>.</li> </ul>	PTO/SB/08) Paper No(s)		
	/Ileana Popa/ Primary Examiner, Art U	nit 1633	

Continuation of 3. NOTE: The amendment to recite that the nucleated cells are monocytes requires further searches and considerations for relevant art.

Continuation of 13. Other: The applicant argues that the examiner has misinterpreted the claims. This is not found persuasive because plasma is the nucleated cell diluted layer. Thus, similar to the instant claims, the combination of the cited art teaches introducing in order: the unecessary cells, the nucleated cell-diluted layer, and the layer rich in nucleated cells. The argument of unexpected results is not found persuasive because separation by first introducing the layer rich in unecessary cells followed by the layer rich in nucleated cells was already taught by both Oka and Fukuda. The applicant argues that Oka and Fukuda are both related to removing and not to the recovery of the nucleated cells. This is not found persuasive. Both Oka and Fukuda teach their method as being very efficient in retaining the nucleated cells on the filter. Thus, even if they do not specifically teach recovering the nucleated cells, they do teach the advantage of first introducing the layer rich in unecessary cells followed by the layer rich in nucleated cells for efficient separation of nucleated cells from erythocytes.